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Aim: About 2% of lung adenocarcinomas have BRAF mutations. The BRAF inhibitors
(BRAFi) vemurafenib (V) and dabrafenib (D) had promising activity in first clinical
trials, but only few centers participated, and many patients (pts) were not enrolled.
Our aim was to study the clinical course of those pts.
Methods:We conducted a retrospective ulticentre cohort study in Europe of pts with
advanced BRAF-mutant lung cancer treated outside of a clinical trial. Data were
anonymized and centrally assessed for age, gender, smoking, histology, stage, local
molecular diagnostic results, systemic therapies, and survival. Best response was
locally assessed by RECIST1.1. This academic study was conducted without industry
support.
Results: By December 2014, 35 pts received individual BRAFi therapy in 17
participating centers. Median age at diagnosis was 64 years (range 43-85), 18 (51%)
male, 16 (46%) current or former smoker. All 35 (100%) pts had lung
adenocarcinoma histology, 29 (83%) had BRAF V600E, 6 (17%) had other BRAF
mutations, 1 (3%) also had a concomitant KRAS mutation. 30 (86%) pts had prior
chemotherapy, 5 (14%) had frontline BRAFi therapy. BRAFi used were V (28 pts), D
(10 pts), and sorafenib (S, 1 pt). 31 (89%) pts received 1 BRAFi (24 V, 7 D) and 4 pts
received 2 (V followed by D in 3 pts, S followed by V in 1 pt). Best response by
RECIST was available for 36 (92%) of 39 BRAFi therapies: 2 (6%) CR, 17 (47%) PR,
13 (36%) SD, and 4 (11%) PD; overall response rate (ORR) was 53% (95%CI:
35-70%). Among the 6 pts with non-V600E, 1 (17%) achieved a PR. No unexpected
toxicities were reported. Further results including updated survival will be presented
at the meeting.
Conclusions: These results support BRAF testing in advanced lung
adenocarcinoma, and BRAFi therapy in patients with V600E. Further studies
are warranted to evaluate combination therapies and potential drug resistance
mechanisms.
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